Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | KCNA3 | P22001 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2994923 | 0.88 | MAPT (0.40) | MAPTSLC6A2SLC6A4CHRM3ALDH1A1 | |
| SCHEMBL4092886 | 0.76 | SLC6A2 (0.41) | SLC6A2SLC6A4KCNA3 | |
| SCHEMBL4092897 | 0.76 | SLC6A4 (0.34) | SLC6A2SLC6A4 | |
| SCHEMBL348555 | 0.73 | ALDH1A1 (0.40) | ALDH1A1 | |
| SCHEMBL2795442 | 0.71 | ALDH1A1 (0.51) | MAPTALDH1A1TP53LMNAHTT | |
| SCHEMBL2988124 | 0.69 | ALDH1A1 (0.43) | MAPTALDH1A1TP53LMNAHTT | |
| SCHEMBL2986864 | 0.69 | ALDH1A1 (0.46) | MAPTALDH1A1TP53LMNAHTT | |
| SCHEMBL2978592 | 0.69 | AKR1C1 (0.53) | SLC6A2SLC6A4CHRM3ALDH1A1TP53 | |
| SCHEMBL2987151 | 0.69 | ALDH1A1 (0.49) | MAPTSLC6A2CHRM3ALDH1A1TP53 | |
| SCHEMBL4951339 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090082367-A1 | TRIAZOLE DERIVATIVE OR A SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-03-26 | — | — | US | disclosed |
| EP-1995243-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2008-11-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082367-A1 | TRIAZOLE DERIVATIVE OR A SALT THEREOF | HSD11B1, HSD11B2, HSD17B1 | MAPT 3869/4885SLC6A2 1397/4885SLC6A4 704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.